| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_85b959d2100bb308fcf773d125a37ab8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-5412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4737 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-58 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate |
2005-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_654766939c0713a5a51ef4773fe41f07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cfc813f0a48a7174de5ea48744135ab |
| publicationDate |
2011-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7960123-B2 |
| titleOfInvention |
Multimarker panel based on PIGF for diabetes types 1 and 2 |
| abstract |
The present invention relates to a method and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention particularly relates to a method for diagnosing whether a diabetes patient is suffering from a cardiovascular complication or is at risk of suffering from a cardiovascular complication, said method comprising the steps of (a) measuring, preferably in vitro, the level(s) of at least one cardiac hormone or a variant thereof in a sample from the patient, and (b) diagnosing the cardiovascular complication or the risk of suffering from cardiovascular complication by comparing the measured level(s) to known level(s) associated with the cardiovascular complication or risk. The present invention also relates to combining the measurement of markers comprising cardiac hormones, natriuretic peptides, inflammation-associated markers, angiogenesis-markers, and markers for platelet activation. Preferred markers are brain natriuretic peptides (particularly NT-proBNP), PlGF, and sCD 40 L. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11446009-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011137131-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9274126-B2 |
| priorityDate |
2004-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |